The Difference Between Public Science and NDA-Level Review

Why research-stage biotech companies aim to communicate clearly without over-disclosing protected technical information

At Biotech International Institute, we believe strong scientific communication requires balance. A research-stage biotech company should be clear enough for partners, investors, universities, CROs, and the public to understand what it is working toward. But it should also be careful enough to protect confidential information, intellectual property, technical strategy, and unfinished validation work.

That balance matters.

If a company says too little, serious partners may not understand the opportunity. If a company says too much, it may expose sensitive science, weaken patent strategy, confuse public audiences, or disclose information before it has been properly validated. That is why today's topic is worth exploring:

The difference between public science and NDA-level review.

Public science has a purpose

Public science refers to what a company can responsibly share on its website, blog, LinkedIn, public summaries, media pages, and non-confidential partner outreach. The goal of public science is not to reveal everything. The goal is to help people understand the company's direction, scientific philosophy, platform categories, validation strategy, and partner needs. For BII, public science may address:

• what BII is working toward

• what platform areas are under development

• what scientific questions are being explored

• what stage the programs are in

• why validation matters

• what types of partners may be relevant

• why responsible communication is important

Public science should be clear, but it should remain high-level.

It should support trust without exposing confidential details.

NDA-level review has a different purpose

NDA-level review is intended for qualified parties who require deeper access to confidential materials after an appropriate confidentiality agreement is in place. This may include certain investors, strategic partners, CROs, academic collaborators, patent counsel, regulatory advisors, technical consultants, or pharmaceutical partners. NDA-level review may include information that is not appropriate for public distribution, such as:

• chemical structures

• molecule design details

• synthetic routes

• detailed assay results

• potency or selectivity data

• confidential AI-assisted review outputs

• unresolved technical questions

• patent prosecution strategy

• detailed risk analysis

• internal budget strategy

• non-public partner notes

• proprietary formulation details

• technical study designs prior to filing or protection

• confidential data-room documents

This material may be relevant for serious diligence, but it should be shared carefully.

Why the distinction matters

The distinction between public science and NDA-level review is intended to protect the company. It may help protect intellectual property, technical strategy, and future partner discussions. It also helps protect the public from misunderstanding early-stage science, and supports overall credibility. A research-stage company should not communicate as though every internal idea is ready for public use.

Some information may be appropriate for public education.

Some may belong in an investor-safe summary.

Some may belong in a CRO-ready technical package.

And some may belong only under NDA.

Public communication should avoid overclaiming

Public materials should not read like clinical claims. This is particularly important for BII's neurological platforms. Neurophorol™, Mycophorol™, and NeuroReset™ are research-stage and patent-pending. They are not approved medicines. They have not been evaluated for human safety or efficacy. Public materials should therefore avoid language that could be interpreted as implying:

• the platform treats disease

• the platform cures a condition

• the platform repairs the brain

• the platform reverses addiction

• the platform has demonstrated human benefit

• the platform is clinically validated

• the platform is ready for medical use

Instead, public materials should use responsible, stage-appropriate language such as:

• research-stage

• patent-pending

• exploring mechanism

• designed for validation

• focused on biological questions

• seeking independent confirmation

• intended for partner-led development

This language is more accurate and supports future regulatory discipline.

Public science should still be meaningful

Being careful does not mean being vague. BII may still communicate meaningfully in public materials. Public content can discuss broad scientific themes such as:

• neuroinflammation

• neuroplasticity

• neurotrophic signaling

• recovery biology

• cannabinoid receptor science

• fungal-inspired biology

• precision peptide platforms

• AgBio livestock protection

• field validation

• bioactive formulation

• partner-led development

• AI-assisted technical organization

These topics may help the public and potential partners understand BII's general direction, provided they are discussed as research areas rather than proven outcomes.

What should stay out of public materials

Certain information should generally remain out of public-facing content unless counsel and leadership determine otherwise. This may include:

• detailed molecule structures

• exact substitutions or chemical series

• precise lead rankings

• confidential formulation details

• synthesis conditions

• protected manufacturing methods

• undisclosed patent strategy

• unresolved technical questions

• exact assay values

• internal AI review outputs

• details of partner negotiations

• internal financial assumptions

• non-public investor conversations

• confidential whitepaper content

Public content should invite serious interest. It should not function as a full technical data room.

Why investors may need a separate layer

Investor communication often sits between public science and NDA-level review. An investor may need more context than the general public, but not every investor should receive full confidential technical materials immediately. Investor-appropriate materials might include:

• company overview

• portfolio summary

• market framing

• validation roadmap

• use-of-funds summary

• high-level IP position

• milestone plan

• partner strategy

• non-confidential technical overview

• risk and mitigation summary

This may provide investors with enough context to understand the opportunity while protecting sensitive scientific information. If interest becomes serious, the conversation may move into NDA-level diligence.

Why CROs may need technical clarity

CROs generally require a different kind of information than the general public or investors. They typically need defined technical instructions rather than public-facing summaries. A CRO-ready package might include:

• test article description

• assay objective

• biological target

• endpoint requirements

• controls

• concentration or dose planning

• sample handling

• deliverables

• expected timeline

• success criteria

• reporting format

Some CRO materials may require confidential disclosure, which is why the data room should separate CRO-ready summaries from deeper NDA-level technical details.

Why universities may need research framing

Academic partners generally need scientific clarity, but not the same materials as investors or CROs. A university laboratory may need to understand:

• the biological question

• the research rationale

• the potential contribution to the field

• what models may be relevant

• what endpoints may be meaningful

• what can be published

• what must remain confidential

• what role the university would play

Academic collaboration tends to work best when the company respects both scientific freedom and IP protection, which requires clear boundaries from the outset.

How this may apply to BII's platforms

BII's portfolio includes several platform areas that require careful communication.

Neurophorol™ may be discussed publicly as a research-stage, patent-pending platform exploring receptor-selective small-molecule biology in the context of neuroinflammation. Under an NDA, qualified reviewers may receive more detailed information on chemical design, receptor strategy, technical questions, validation needs, and supporting technical review.

Mycophorol™ may be discussed publicly as a fungal-inspired neurotrophic-pathway research platform. Under NDA, a deeper review may include structural questions, analytical confirmation needs, pathway considerations, and confidential technical details.

NeuroReset™ may be discussed publicly as an earlier-stage multi-target neuroplasticity and recovery-biology concept. Under NDA, a deeper review may involve lead-definition strategy, conjugate design, stability questions, and future validation planning.

AgriShield-X™ may be discussed publicly as a research-stage livestock protection platform exploring plant-derived bioactives, encapsulated delivery, and field validation. Under NDA, a deeper review may include formulation details, component considerations, field protocols, patent strategy, and regulatory planning.

Each platform may benefit from both public clarity and protected technical depth.

The role of a data room

A data room may help manage the difference between public science and NDA-level review by organizing materials by access level:

Public — Website pages, blog posts, LinkedIn summaries, public PDFs, non-confidential platform overviews.

Investor-safe — Pitch decks, use-of-funds summaries, milestone plans, non-confidential technical summaries, public validation roadmap.

Academic partner — Research questions, study concepts, collaboration summaries, publication-sensitive materials.

CRO-ready — Assay scopes, sample requirements, deliverables, study objectives, controlled technical instructions.

NDA-only — Detailed technical reports, structures, confidential validation plans, unresolved technical questions, prosecution strategy, and internal risk analysis.

This structure may help keep communication professional and reduce the risk of accidental over-disclosure.

AI-assisted review should be handled carefully

BII has used AI-assisted tools as part of technical organization and planning.

Publicly, BII may note that AI-assisted tools can support technical organization, literature mapping, hypothesis refinement, validation planning, and document preparation. Under NDA, deeper AI-assisted technical review may be shared where appropriate. In all cases, however, the context should remain clear:

AI tools do not demonstrate efficacy. They do not replace laboratory validation, CROs, universities, or regulatory review. They may help organize questions, but independent data is what answers them.

Why this approach may strengthen BII's credibility

Clear communication boundaries may strengthen BII's standing by demonstrating awareness of:

• intellectual property protection

• research-stage responsibility

• partner diligence

• regulatory sensitivity

• investor communication standards

• technical review expectations

• public trust

This is how BII may operate more like a serious biotech company — not by revealing everything or overclaiming, but by communicating the right information at the right level.

A guiding principle for BII

A useful principle is this:

Public materials should explain the opportunity. NDA-level materials should support the diligence. Public materials help people understand why a platform may matter. NDA-level materials help qualified reviewers evaluate whether it is scientifically and strategically credible. Those are different purposes. Both are necessary.

Closing thought

Research-stage biotech companies must communicate carefully.

They may need public clarity, investor-safe summaries, CRO-ready packages, academic collaboration materials, and NDA-level technical review.

At BII, the goal is to build a communication system that helps protect the science while making the company easier to understand, review, and partner with.

Research-stage. Patent-pending. Built for validation.
Mechanism first. Validation always.